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Abstract
Background: Postoperative delirium (POD) is a manifestation of acute postoperative brain dysfunction that is
frequently observed after cardiac surgery. POD is associated with short-term complications such as an increase in
mortality, morbidity, costs and length of stay, but can also have long-term sequelae, including persistent cognitive
deficits, loss of independence, and increased mortality for up to 2 years. The noble gas xenon has been demonstrated
in various models of neuronal injury to exhibit remarkable neuroprotective properties. We therefore hypothesize that
xenon anesthesia reduces the incidence of POD in elderly patients undergoing cardiac surgery with the use of
cardiopulmonary bypass.
Methods/Design: One hundred and ninety patients, older than 65 years, and scheduled for elective cardiac surgery,
will be enrolled in this prospective, randomized, controlled trial. Patients will be randomized to receive general
anesthesia with either xenon or sevoflurane. Primary outcome parameter will be the incidence of POD in the first 5
postoperative days. The occurrence of POD will be assessed by trained research personnel, blinded to study group,
with the validated 3-minute Diagnostic Confusion Assessment Method (3D-CAM) (on the intensive care unit in its
version specifically adapted for the ICU), in addition to chart review and the results of delirium screening tools that will
be performed by the bedside nurses). Secondary outcome parameters include duration and severity of POD, and
postoperative cognitive function as assessed with the Mini-Mental State Examination.
Discussion: Older patients undergoing cardiac surgery are at particular risk to develop POD. Xenon provides
remarkable hemodynamic stability and has been suggested in preclinical studies to exhibit neuroprotective
properties. The present trial will assess whether the promising profile of xenon can be translated into a better
outcome in the geriatric population.
Trial registration: EudraCT Identifier: 2014-005370-11 (13 May 2015).
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Background
Postoperative delirium (POD) is frequently observed
after cardiac surgery with incidences ranging from 20
to 80 % [1, 2]. It is associated with short-term compli-
cations such as an increase in mortality, morbidity,
costs and length of stay, but is also associated with
long-term sequelae, including the development of
persistent cognitive deficits, loss of independence, and
increased mortality for up to 2 years [3].
The pathophysiology of POD is complex and thought
to be related to cerebral ischemia-reperfusion injury,
endothelial dysfunction [4], neuroinflammation [5], neu-
rotransmitterimbalances [6, 7] and direct neurotoxic ef-
fects of anesthetics [8]. The individual baseline risk of a
patient to develop POD is determined by a variety of pre-
disposing factors that are not possible to be modified, in-
cluding age, male gender, psychiatric illness, cognitive
impairment (e.g. dementia) and atherosclerotic disease [2].
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POD has been suggested to be precipitated by intra-
operative and postoperative triggers. In contrast to the
predisposing factors, precipitating factors are amenable
to modification and have thus become a target of pre-
vention strategies. Unfortunately, the unambiguous
identification of precipitating factors for POD remains
notoriously difficult. Numerous elements have been de-
scribed, including (but not limited to) cardiovascular
surgery, use of cardiopulmonary bypass (CPB), applica-
tion of anesthetics and cognitively active medication,
hypotension, decreased cardiac output, hypothermia
and hypoxia [9, 10].
The noble gas xenon has been shown to offer neuro-
protection in numerous in-vitro and in-vivo models of
neuronal injury including models of post-cardiac sur-
gery neurocognitive dysfunction [11, 12]. Neuroprotec-
tion by xenon is most likely achieved by diverse
mechanisms including antagonism at the N-methyl-D-
aspartate (NMDA) subtype of the glutamate receptor
[13], an enhanced synthesis of prosurvival (B-cell
lymphoma 2 and extra large) proteins and the suppres-
sion of neuronal apoptosis [14, 15]. Moreover, xenon
preserves cerebral flow-metabolism coupling [16, 17]
and possesses anti-inflammatory qualities that may dir-
ectly interfere with the pathogenesis of POD [18]. Fur-
thermore, the favorable physicochemical properties of
xenon result in rapid clearance from the brain, thereby
reducing any residual anesthetic effects that may pre-
dispose to POD [19, 20]. Last, xenon has been repeatedly
demonstrated to cause less hemodynamic deterioration
than conventionally used anesthetics [21–23]; therefore, it
helps to avoid hemodynamic instability which is a precipi-
tating factor for POD.
Therefore, we hypothesize that in older cardiac surgi-
cal patients, the use of xenon anesthesia significantly re-
duces the incidence of POD when compared to the
conventionally used anesthetic sevoflurane. Additionally,
the evaluation of outcome will include several secondary
endpoints such as the duration and severity of POD,
postoperative cognitive function as analyzed with the
Mini-Mental State Examination (MMSE), length of in-
tensive care unit (ICU) stay, hospital length of stay, the
incidence of postoperative organ dysfunction and the in-
cidence of (serious) adverse events ((S)AE).
Methods/Design
Study registration
The study will be performed according to the principles
of the International Declaration of Helsinki and to the
principles of good clinical practice (GCP) and is approved
by the ethics committee of the University Hospitals
Leuven, by the Clinical Trials Centre of the University
Hospital Leuven, and by the “Federaal Agentschap voor
Geneesmiddelen en Gezondheidsproducten.” The study
is registered in the European Clinical Trials Database
of the European Medicines Agency (EudraCT Identi-
fier: 2014-005370-11, 13 May 2015). Any eventual
changes of the study protocol will be reported to the
ethics committee.
Recruitment
Patients will be recruited by the principal investigator or
co-investigator. Detailed information about the study
background and protocol will be given, and any possible
questions brought forward by the patients will be an-
swered. Each eligible patient who is willing to participate
in the study will sign a written informed consent before
any particular study procedure.
Study type
This prospective, randomized, controlled trial will be
performed at the University Hospital of the KU Leuven
by two types of investigators. Investigator I will assess
the primary outcome (and the majority of the secondary
outcome parameters) and is blinded to the group affili-
ation. Investigator II will perform anesthesia and cannot
be blinded to the treatment groups due to the adminis-
tration of the anesthetic via a dedicated anesthesia ma-
chine and the mandatory monitoring of anesthetic
concentrations [24].
Randomization
Patients will be randomized using a computer-generated
permuted block randomization sequence (variable block-
size, 1:1 allocation). Randomization will be stratified by
the European System for Cardiac Operative Risk Evalu-
ation (EuroSCORE) II (Stratum I: EuroSCORE ≤ 3;
Stratum II: EuroSCORE > 3). A masked randomization
procedure will be used in which group assignments are
hidden in sealed, opaque, sequentially numbered enve-
lopes that will only be opened upon arrival of the patient
to the operation room (OR).
Inclusion criteria
 Age > 65 years
 Patient scheduled for elective heart surgery with the
use of CPB
 Able to read and understand the research materials
Exclusion criteria
 Inability to give informed consent
 Intraoperative need for one-lung-ventilation and/
or for an increased fraction of inspired oxygen
(FiO2 > 50 %)
 Chronic obstructive pulmonary disease (COPD)
GOLD > II
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 Critical preoperative state (as defined by the
requirement of inotropic support or intra-aortic
balloon pump (IABP), ventricular tachycardia or
ventricular fibrillation, preoperative cardiac
massage, preoperative ventilation before anesthetic
room, preoperative acute renal failure (anuria or
oliguria < 10 ml hr−1) [25]
 Disabling neuropsychiatric diseases (dementia,
schizophrenia, epilepsy or mental retardation)
 Presence of delirium at baseline as screened with
the 3-minute Diagnostic Confusion Assessment
Method (3D-CAM) [26]
 Alcohol abuse: (defined as a CAGE score ≥ 2) [27]
 History of drug abuse
 History of stroke or traumatic brain injury with
residuals
 Increased intracranial pressure
 Hypersensitivity to the study medications
 Risk for malignant hyperthermia
Anesthesia and intervention
The different steps of the study visits are summarized
in Fig. 1.
Baseline assessment (Investigator I)
Investigator I will obtain written informed consent and
record baseline data (demographic data, medical and
surgical history, routine clinical examination, Charlson
comorbidity index (CCI) [28], results of preoperative chest
X-ray, electrocardiogram (ECG) analysis, echocardiog-
raphy and standard laboratory parameters). In addition,
the MMSE [29], the 3D-CAM, the Geriatric Depression
Scale (GDS) [30] and an interview with a family member
using the short form of the Informant Questionnaire on
Cognitive Decline in the Elderly (IQCODE) [31] will be
performed the day before surgery. Patients with alcohol
abuse will be identified with the CAGE questionnaire [27]
and excluded. Besides, patients’ preoperative functional
status will be assessed using the Katz Index of Activities of
Daily Living (ADL) [32].
General anesthesia
Patients must be in a fasting state for 6 hours prior to
anesthesia. Patients will be premedicated with lorazepam
per os 0.03 mg kg−1 1 hour before surgery (patients >
80 years with lorazepam 0.015 mg kg−1).
After 5 minutes of pre-oxygenation (FiO2 = 1.0),
general anesthesia will be induced with a combination
Fig. 1 Schematic illustration of the study visits. 25-OHD, 25-hydroxy vitamin D; 3D-CAM, 3-minute Diagnostic Confusion Assessment Method; AE,
adverse event; APACHE II, Acute Physiology and Chronic Health Evaluation II; BIS, bispectral index; CAM-S, Confusion Assessment Method Severity
score; CCI, Charlson Comorbidity Index; DOS, Delirium Observation Scale; GDS, Geriatric Depression Scale; ICDSC, Intensive Care Delirium Screening
Checklist; ICU, intensive care unit; IL, interleukin; IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; Katz ADL, Katz Index of
Activities of Daily Living; MMSE, Mini-Mental State Examination; NIRS, near-infrared spectroscopy; RASS, Richmond Agitation-Sedation Scale; SAPS,
Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment score; SAE, serious adverse events; TEE, transesophageal echocardiography
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of remifentanil 0.5 μg kg−1 min−1 followed by a bolus
of intravenous propofol 0.5–1 mg kg−1. Tracheal in-
tubation will be facilitated by the bolus administration
of cisatracurium (0.2 mg kg−1). Afterwards, the sealed
randomization envelopes will be opened and patients
will be randomly allocated to the two treatment
groups in which general anesthesia will be maintained
with either:
 xenon 40–60 % in oxygen (FiO2 = 0.5–0.6) (xenon-
group), or
 sevoflurane 1.0–1.4 % (FiO2 = 0.5–0.6) (sevoflurane-
group)
In both groups, anesthetic concentrations will be ti-
trated according to the clinical observation of vegetative
signs for the depth of anesthesia (including heart rate
(HR), blood pressure, sweating, etc.) and to the instant-
aneously registered electroencephalogram (EEG)-moni-
toring in order to reach a bispectral index (BIS) value
between 40 and 60. Cisatracurium will be administered
at the induction of anesthesia. Further curarization will be
left upon the discretion of the attending anesthesiologist.
Analgesia will be achieved with a continuous infusion
of remifentanil (0.15–0.25 μg kg−1 h−1), starting after in-
duction of anesthesia. The dose of remifentanil will be
adjusted by increments of 0.05 μg kg−1 min−1 when the
patient develops sweating, shows spontaneous move-
ments and/or a sudden increase in HR or arterial pres-
sure by more than 20 % [33]. During the CPB period, the
investigational treatment will be discontinued in both
groups and replaced with a target-controlled infusion
(TCI) of propofol with calculated plasma concentra-
tions of 1–2 μg ml−1 that will be titrated according to
the BIS-monitoring. After completion of surgery, the
interventional treatment will be stopped, and a bolus of
intravenous (IV) piritramide 0.2 mg kg−1 will be given.
Patients will be transferred to the ICU under mono-
sedation with propofol.
Monitoring and hemodynamic management
Hemodynamic and respiratory monitoring will be pro-
vided according to our institutional routine including
the placement of an arterial, a central venous and a pul-
monary artery catheter. Whenever available, the follow-
ing parameters will be recorded every 15 minutes from
the pre-anesthetic period to the end of surgery: periph-
eral oxygen saturation (SpO2), invasive arterial blood
pressure (IBP), HR, central venous pressure (CVP), car-
diac output (CO), mixed venous oxygen saturation
(SvO2), mean pulmonary artery pressure (MPAP), frac-
tion of inspired oxygen (FiO2), end-tidal carbon dioxide
(etCO2), body temperature, BIS, urine output, blood loss.
Additionally, cerebral tissue oxygenation (rSO2) will be
assessed by near-infrared spectroscopy (NIRS). Besides,
transesophageal echocardiography (TEE) will be per-
formed during anesthesia according to our institutional
standards. Fixed measurements will be achieved for blood
gas and a complete hemodynamic profile at the following
time points: T0 = prior to induction, T1 = after induction,
T2 = after sternotomy, T3 = after weaning from CPB, T4 =
after sternal closure and T5 = end of surgery.
Intraoperative hemodynamic management will be stan-
dardized according to our clinical routine. Basic fluid
substitution will be performed with 1 ml kg−1 h−1 bal-
anced crystalloid solution. Hemodynamic stability will
be defined as cardiac index > 2.5 L min−1 m−2, SvO2 >
70 % and mean arterial blood pressure of > 65 mmHg
(between 50 and 60 mmHg during CPB). In case of
hypovolemia (as detected by TEE or visual inspection
of the heart), colloid solutions (gelatin) will be infused.
Packed red blood cells (PC) will be transfused when the
hemoglobin content is less than 8.0 g dL−1. A norepineph-
rine infusion will be administered when hemodynamic
stabilization cannot be achieved despite adequate volume
loading. The administration of inotropes, vasodilators, PC,
fresh frozen plasma (FFP) and platelets will be left at the
discretion of the attending anesthesiologist.
Cardiopulmonary bypass
CPB will be performed in mild to moderate hypothermia
on a conventional CPB circuit with cardiac arrest induced
by antegrade or retrograde infusion of cold crystalloid car-
dioplegic solution. Extracorporeal circulation will be per-
formed with a pump flow of 2.2–2.5 L min−1 m−2. Prior to
CPB, 300–350 IU kg−1 heparin will be administered to
achieve an activated clotting time of > 400 s. After
weaning from CPB, heparin will be antagonized with
protamine in a ratio of 1:1. Furthermore, propofol
TCI will be stopped and the investigational treatment
will be re-administered.
Intensive care unit treatment
On the ICU, analgesia will be achieved with a continu-
ous infusion of piritramide, supplemented by systemic
acetaminophen (1–2 g, administered IV every 8 hours)
during the first postoperative day. Standard tracheal extu-
bation and patients discharge criteria will be applied.
As part of standard care, a bundle of non-
pharmacological interventions will be applied to prevent
delirium, including:
 Active detection and treatment of pain
 Early mobilization
 Removal of catheters, drains, probes, etc. as soon as
possible
 Timely recognition and treatment of medical
problems such as stroke, infections, electrolyte
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imbalances, hypoxia, heart failure, hypotension,
dehydration, urinary retention, etc.
 Strict avoidance of medications known to trigger
POD (in particular, benzodiazepines and steroids)
Whenever a POD occurs, pharmacological treatment
based on our institutional standards of care, will be intiated.
Once standard discharge criteria will be met, the pa-
tients will be transferred to the ward.
Study outcomes
Primary endpoint
Incidence of postoperative delirium as assessed by 3D-
CAM and/or CAM-ICU.
The primary study endpoint will be the incidence of
POD during the first 5 postoperative days. Hence, the
null hypothesis states that there is no difference between
both groups in POD incidence (yes/no) during the first 5
postoperative days. Through ICU-stay, patients will be
assessed daily for the presence of POD by trained re-
search nurses (blinded to the group assignment) using
the CAM adapted for the ICU (CAM-ICU) [34]. In
addition, we will perform a daily chart review for the re-
sults of the Intensive Care Delirium Screening Checklist
(ICDSC) [35] over the previous 24 hours, which is a
standard assessment, conducted during each 8-hour shift
by the bedside ICU nurse. Patients with a Richmond
Agitation-Sedation Scale of < −3 will be considered un-
conscious and not evaluable for POD [36]. After trans-
feral to the ward, patients will be assessed by trained
research personnel on a daily basis for the presence of
POD using the 3D-CAM. In addition, we will perform a
daily chart review for the results of the Delirium Obser-
vation Scale (DOS) [37] over the previous 24 hours that
will be conducted by the nurses. On both the ICU and
the ward, the patients’ records over the previous 24-hour
period will be checked to identify key words suggestive of
POD (e.g. confused, agitated, aggressive, disorientated,
drowsiness and delirious) and the administration of anti-
psychotic therapy [38, 39].
Secondary endpoints
Secondary endpoints include the duration of POD (total
number of days and percentage of patients with duration
of POD longer than 2 days; for patients who have POD
on day 5, daily clinical assessments are continued until
the symptoms resolve or until the patient is discharged),
the severity of POD (assessed with the delirium severity
measure based on CAM (CAM-S) [40], use of physical
restraints, postoperative cognitive function as analyzed
with the MMSE at postoperative day 3, day 5, the day
before discharge and at 6 months post surgery, and pre-
operative and postoperative ADL functioning as analyzed
with the Katz ADL scale at baseline and the day be-
fore discharge and at 6 months post surgery.
In addition, the administration of anti-delirium medi-
cations (such as haloperidol, anxiolytics, dexmedetomi-
dine, etc.) and duration of sedation will be registered
and compared between both groups.
Other secondary endpoints will be:
 Incidence of MACCE (major adverse cardiac and
cerebral events, occurring until discharge from
hospital and in the first 6 postoperative months);
i.e. death from any cause; perioperative myocardial
infarction, requirement of surgical revisions at the
coronary arteries; postoperative coronary
angioplasty; and stroke. Myocardial infarction is
defined as the occurrence of a new Q wave in
addition to a rise of more than 10 ng ml−1 of
troponin in the early postoperative period or any
episode of chest pain with typical rise and fall of
cardiac enzymes thereafter
 Other cerebrovascular accidents not included in
MACCE (transient ischemic attacks, reversible
ischemic neurologic deficit)
 Postoperative renal function (as assessed by
serum creatinine and blood urea nitrogen
(BUN) levels)
 Requirement for blood (product) transfusion
 Incidence of intraoperative awareness as detected by
the use of a structured Brice questionnaire [41] that
will be performed one day after ICU discharge
 Duration of postoperative ICU-stay and hospital stay
 Severity of postoperative critical illness as indicated
by the Acute Physiology and Chronic Health
Evaluation (APACHE) [42] II score once within
24 hours after admission to the ICU and the
Sequential Organ Failure Assessment (SOFA)
score [43]
 Incidence of serious adverse events (SAE) and
suspected unexpected serious adverse reactions not
included above. According to the International
Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals
for Human Use (ICH), an adverse event (AE) will
be defined as “any untoward medical occurrence in
a patient or clinical investigation subject
administered a pharmaceutical product and which
does not necessarily have to have a causal
relationship with this treatment.” A SAE is “any AE
that is life threatening – results in death – requires
patients re-hospitalization and/or prolongation of
existing hospitalization – or results in patient’s
disability” [44]
 Intraoperative hemodynamic and respiratory profile
 Intraoperative use of inotropic/vasoactive medication
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Blood samples and laboratory parameters
Because of a possible correlation between preoperative
vitamin D levels and the occurrence of POD, serum-
levels of 25-hydroxy vitamin D (25-OHD) will be
checked for all patients preoperatively [45, 46]. Further-
more, different blood samples will be collected at base-
line (visit 0), at 1 hour after end of surgery (visit 2) and
postoperative day 1 (visit 3). From these samples, the
following parameters will be examined:
 Markers of glial injury: serum protein S100β
 Hemoglobin and hematocrit
 Cardiac markers: CK-MB and troponin T-hs
 C-reactive protein (CRP), leukocyte counts, serum
cytokines (interleukin (IL)-6, IL-10)
 Respiratory markers: SaO2, PaO2 PaCO2, arterial
pH, bicarbonate and base excess
 Renal markers: serum creatinine and blood urea
nitrogen
 Hepatic markers: serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST), gamma-
glutamyl transferase (GGT) and total bilirubin
 Serum electrolytes and serum blood sugar
concentration
Additional blood samples may be collected, at the inves-
tigator’s or other physician’s judgment, in case of technical
problems during the initial assay performed or missing
baseline values prior to surgery and/or clinical abnormal-
ities necessitating specific additional measurements.
Statistical analysis and sample size calculation
All statistical analyses will be performed using a com-
mercially available software package (SAS software, ver-
sion 9.2 of the SAS System for Windows, SAS Institute
Inc., Cary, NC, USA). All tests will be 2-sided, and a p <
0.05 will be considered to indicate statistical significance.
For the primary outcome, the incidence of POD, a lo-
gistic regression adjusting for the stratification variable
EuroSCORE will be used to compare both groups. Sensi-
tivity analyses will be performed to evaluate the impact
of the non-evaluable patients (expected to be less than
5 %: e.g. deceased patients, transferred to other centers,
extremely sedated patients) during the 5 postoperative
days. First, a “worst case scenario” will be considered as-
suming absence of POD for all non-evaluable patients in
the conventional anesthesia group and presence of POD
for all non-evaluable patients in the xenon-anesthesia
group. Second, a multiple imputation approach will be
used imputing a POD value for the non-evaluable pa-
tients, with as imputation model a logistic regression fitted
in both groups separately [47] with baseline characteristics
as categorical and continuous predictors. Twenty imputed
datasets will be created and results will be averaged
appropriately.
For the secondary outcomes, the used statistical test
will depend on the type and distribution of the consid-
ered outcome. Normally distributed data (verified with
the Shapiro-Wilk W test statistic) will be compared
using an analysis of covariance (ANCOVA) with the di-
chotomized EuroSCORE as binary covariate. Intergroup
comparisons of non-normally distributed data will be
performed using the stratified version of the Mann–
Whitney U test. Differences in proportions will be ana-
lyzed using the exact test for a stratified 2x2 table.
Time-to-events (occurrence of POD) will be assessed
from end of surgery until the occurrence of the POD.
Patients will be censored if they do not experience POD
at the time of the last follow-up. To obtain the
cumulative distribution curves for the POD times,
Kaplan-Meier estimates will be used and groups will
be compared using the stratified log-rank test. A lin-
ear model for longitudinal measurements with an
unstructured covariance matrix for the fixed points in
time (i.e. a multivariate regression model using a
direct likelihood approach) [48] and the dichotomized
EuroSCORE as a binary covariate will be used to
evaluate the evolution of laboratory markers.
The study will be powered to detect the differences in
primary outcome between the sevoflurane-group and
the xenon-group. Based on recent observations from our
institute [49], the incidence of POD after cardiac surgery
with sevoflurane-anesthesia is approximately 40 %. A
comparable incidence has already been reported earlier
by our group [50] and has also been observed by other
investigators [3]. Using a 2-sided test for the detection of
differences between proportions (with alpha = 5 % and
applying a continuity correction), at least 91 patients per
group (182 in total) are required to show with 80 %
power a 50 % reduction in the incidence of POD. To
compensate for possible drop-outs, we will include 190
patients in total. They will be randomized into both
groups in a 1:1 ratio.
Since the needed sample size depends extremely on
the assumed POD rate, a sample size recalculation (SSR)
will be performed after inclusion of 100 patients. This
SSR will be based on a blinded evaluation of the overall
POD rate [51]. Since the SSR is fully blinded (i.e. the
group allocation is not known), this analysis can be per-
formed by a member of the study steering committee.
Applying the assumed relative risk (relative reduction of
the POD by 50 %) on the overall POD rate, the power
will be recalculated. For example, suppose that the over-
all POD rate after inclusion of 50 subjects in each group
equals 24 %, instead of the expected 30 % (40 % and
20 %, respectively). Then, based on the assumed 50 %
relative reduction, this corresponds to 16 % and 32 % for
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xenon and sevoflurane, respectively, which would re-
quire 123 patients in each group instead of 91 patients
to maintain 80 % power. Based on this information, the
study steering committee will decide on extending the
accrual time. Note that based on the result of the SSR,
the planned sample size will only be maintained or in-
creased (not lowered).
Discussion
The primary aim of the current trial is to test whether
general anesthesia with xenon significantly reduces the
incidence of POD in older patients undergoing elective
cardiac surgery with the use of CPB.
Novelty
Numerous in-vitro and in-vivo studies have shown that
the noble gas xenon owns neuroprotective properties
[11, 52, 53]. Evidence on xenon-mediated neuroprotec-
tion in humans is, however, scarce. To the best of our
knowledge, four randomized controlled trials tested the
efficacy of xenon for the prevention of postoperative
cognitive dysfunction (POCD). Unfortunately, these stud-
ies produced controversial results [19, 20, 54, 55], most
probably owing to the inclusion of heterogenous patient
populations, the diversity in types of surgery, different
follow-up periods in which patients were assessed for
POCD, the use of different test batteries, and – at least in
part – inadequate sample sizes. Moreover, not all studies
focused on patients known to exhibit a particularly high
risk for the development of neurocognitive complications.
Our clinical trial will assess the efficacy of xenon for
the prevention of POD in cardiac surgery. Due to its
scarcity, xenon is extremely costly. These expenses will
only be justified when the promising observations with
xenon in preclinical experiments can be translated into a
better outcome for the geriatric population. POD has
been demonstrated to be associated with important
short-term and long-term complications and occurs par-
ticularly frequently in patients older than 65 years. Our
study will, therefore, focus on an extremely vulnerable
population. We will employ well-validated methods for
delirium screening and also assess long-term neurocog-
nitive function.
Limitations
Investigator II, who performs the xenon or sevoflurane
anesthesia, cannot be blinded to the kind of interven-
tion. However, this investigator will have to adhere to a
strict hemodynamic treatment protocol in order to en-
sure equivalent management in both groups and avoid
bias. Moreover, investigators blinded to the group affili-
ation will assess all postoperative outcomes of the
current trial, including the primary endpoint and the
majority of secondary outcomes.
Furthermore, the noble gas xenon will only be admin-
istered during the intraoperative period. This is exactly
the time period in which neuronal injury leading to
POD and neurocognitive deterioration is expected to
occur and during which neuroprotective interventions
should presumably have the greatest benefit. However,
any potential advantages of xenon with respect to recovery
characteristics could be masked by postoperative events
or interventions in the ICU or the nursing ward.
Benefits for the participating patients
There is no guarantee that the use of xenon, instead of
standard treatment with sevoflurane alone, will provide
any medical advantage to the participant.
Safety issues
The interventional treatment will be administered to pa-
tients under advanced hemodynamic monitoring in the
setting of a fully equipped cardiac surgical operation
room. This enables immediate detection and treatment
of adverse events. Xenon inhalation will be immediately
stopped in case that the study patient will show a life-
threatening deterioration. After leaving the operation
room, all patients will be closely monitored by the study
team for the occurrence of eventual (S)AEs during the
whole postoperative period until hospital discharge.
Moreover, the inclusion of each individual patient into
the study is indicated in the electronic hospital informa-
tion system and hence visible to all physicians and
nurses involved in the care of this patient. This will fa-
cilitate reporting of (S)AEs to the principal investigator.
Finally, suspected unexpected serious adverse reactions
will be reported by the principal investigator to the
federal health authorities.
Trial status
The enrollment period is planned over a 36-month
period starting in September 2015. The end of patient
enrollment is expected for October 2018. A subse-
quent period of 6 months is planned for the primary
data evaluation and statistical analysis including the
6-month follow-up for the assessment of long-term
outcome. An additional period of 3 months is planned for
remaining data evaluation, statistical analysis and publica-
tion of the results.
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Flanders; GCP: good clinical practice; GDS: Geriatric Depression Scale;
GGT: gamma-glutamyl transferase; HR: heart rate; IABP: intra-aortic balloon
pump; IBP: invasive blood pressure; ICH: Technical Requirements for
Registration of Pharmaceuticals for Human Use; ICDSC: Intensive Care
Delirium Screening Checklist; ICU: intensive care unit; IL: interleukin;
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly;
IV: intravenous; MACCE: major adverse cardiac and cerebral events;
MMSE: Mini-Mental State Examination; MPAP: mean pulmonary artery
pressure; NMDA: N-methyl-D-aspartate; NIBP: non-invasive blood pressure;
NIRS: near-infrared spectroscopy; OR: operation room; PaCO2: partial pressure
of carbon dioxide in the blood; PC: packed cells; POCD: postoperative
cognitive dysfunction; POD: postoperative delirium; rSO2: regional cerebral
tissue oxygenation; RASS: Richmond Agitation-Sedation Scale; SaO2: arterial
oxygen saturation; SAPS: Simplified Acute Physiology Score; SOFA: Sequential
Organ Failure Assessment score; SAE: serious adverse events;
SpO2: peripheral oxygen saturation; SSR: sample size recalculation;
SvO2: mixed venous oxygen saturation; TCI: target-controlled infusion;
TEE: transesophageal echocardiography.
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